{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:14:14Z","timestamp":1776082454972,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T00:00:00Z","timestamp":1702166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Sebaceous carcinoma (SC) is a rare skin cancer with significant associated morbidity and mortality. A known association exists between immunosuppression, in particular solid organ transplant patients (SOTR), and SC. However, the comparative reporting odds ratios (ROR) of different immunosuppressive medications and SC are incompletely defined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To examine the relationship between SC and medication exposure in the FDA adverse event reporting system (FAERS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Case\u2013control analyses were performed in FAERS from 1968 to 2021 to examine the reporting odds ratios (ROR) for SC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 58 medication\u2010associated SC cases were identified. Immunosuppressant medication exposure was noted in 81% cases, with 20% total cases occurring in SOTR. Medications affecting the TNF\u2010 \u03b1 \u2010IL\u20101\u2010IL\u20102\u2010IL\u20106 inflammatory axis were associated with elevated ROR for SC, including thalidomide (ROR 22.63, 95% CI 5.52\u201392.72), lenalidomide (ROR 10.86, 95% CI 4.93\u201323.94), cyclosporine, tacrolimus, tocilizumab, tofacitinib and ruxolitinib. Thirty per cent of cases of SC occurred with an associated haematologic malignancy or dyscrasia, including chronic lymphocytic leukaemia, non\u2010Hodgkin lymphoma and multiple myeloma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>SC is associated with exposure to immunosuppressive medications, especially in SOTR patients. A significant portion of cases with SC had an associated haematology malignancy, in particular multiple myeloma with exposure to lenalidomide.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.19703","type":"journal-article","created":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T10:39:20Z","timestamp":1702204760000},"page":"937-944","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the <scp>FDA<\/scp> adverse event reporting system"],"prefix":"10.1111","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8950-0965","authenticated-orcid":false,"given":"Patrick M.","family":"Jedlowski","sequence":"first","affiliation":[{"name":"Division of Dermatology University of Arizona College of Medicine \u2013 Tucson  Tucson Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason P.","family":"DuPont","sequence":"additional","affiliation":[{"name":"Division of Dermatology University of Arizona College of Medicine \u2013 Tucson  Tucson Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,12,10]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2473"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30673-4"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13490"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2019.01.006"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23963"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0b013e3181961861"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2001.01233.x"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.08.003"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2012.05627.x"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12564"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000520"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002039"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.799"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1945578"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00334-9"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.6.1305.1305"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-7-16"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.4.11.2199284"},{"key":"e_1_2_11_20_1","volume-title":"StatPearls","author":"Tapia C","year":"2022"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.54.2.137"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/453020"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.10.001"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.728597"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp070449"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2014.01.008"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.29252\/ibj.25.2.88"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T10:36:25Z","timestamp":1714041385000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,10]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/jdv.19703"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19703","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,10]]},"assertion":[{"value":"2023-07-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}